Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week

Understanding ownership research and analyst forecasts can provide insights into stock opportunities. For example, in Syros Pharmaceuticals, institutions hold a 32% stake, indicating potential upside or downside. Analyzing ownership groups, including hedge funds and insiders, along with analyst sentiments, can help assess a company's future prospects.